How Gilead Profited by Slow-Walking a Promising H.I.V. Therapy
Gilead delayed a new version of a drug, allowing it to extend the patent life of a blockbuster line of medications, internal documents show. [Source]
Publication Date:Origin: nytimes.com
Category: Acquired Immune Deficiency Syndrome
Topics: Gilead, documents, internal, medications, blockbuster, patent, extend, allowing, version, delayed, Therapy, Promising, Slow-Walking, Profited
Source: https://www.nytimes.com/2023/07/22/business/gilead-hiv-drug-tenofovir.html